
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): November 12, 2015

ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-33038
(Commission
File Number)

84-1475642
(IRS Employer
Identification No.)

One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts
(Address of Principal Executive Offices)

02129
(Zip Code)

(617) 259-1970
(Registrant's Telephone Number, including Area Code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-
-

Item 7.01 Regulation FD Disclosure

On November 12, 2015, ZIOPHARM Oncology, Inc., or the Company, together with Intrexon Corporation, or Intrexon, will present the attached presentation of the Company's programs and collaborations in the field of immuno-oncology at Intrexon's Investor Day in New York, New York, on November 12, 2015.

A copy of the above referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation of the Company dated November 12, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

By: /s/ Caesar J. Belbel

Name: Caesar J. Belbel

Title: Chief Operating Officer, Executive Vice President, Chief Legal Officer and Secretary

Date: November 12, 2015

INDEX OF EXHIBITS

**Exhibit
No.**

Description

99.1 Presentation of the Company dated November 12, 2015

INTREXON[®]

Harnessing the power of
the immune system to fight cancer


Laurence Cooper M.D., Ph.D.
Chief Executive Officer, ZIOPHARM Oncology, Inc.



Synthetic Biology Leads to Powerful Engineering of Immune System


Effective immunotherapy must be fashioned outside the body to work effectively inside the body

- Immune cells are capable of preventing and eliminating disease
- Yet the body's own programming language governing an immune response is unable to eliminate tumor cells
- Genes can be engineered *ex vivo* to achieve *in vivo* anti-tumor effects





Intrexon & ZIOPHARM: Delivering Multimodal Gene Therapies


Cell Therapy CAR-T, TCR and NK Cells Autologous and Allogeneic



Viral Therapy



Viral & Non-viral Gene Integration



Viral Gene Therapy: Ad-RTS-IL12 Ongoing Trials

Multi-Center Phase I Study of IL-12 Gene Therapy in Recurrent or Progressive Glioblastoma / Grade III Malignant Glioma

- A single cycle of Ad-RTS-hIL-12 & escalating veledimex
- To establish:
 - Efficiency of veledimex crossing human BBB
 - Safety and tolerability
 - Determine MTD and immune response
 - Anti-tumor activity



Phase 1b/2 Study of IL-12 Gene Therapy in Locally Advanced / Metastatic Breast Cancer

- A single cycle of Ad-RTS-hIL-12 + veledimex
- Goal of maintaining or improving pre-study response
- To establish:
 - Safety and tolerability
 - Anti-tumor activity



ZIOPHARM Oncology



Memorial Sloan Kettering
Cancer Center.

Portfolio of Cell Therapies to Address Oncology Landscape

CAR⁺ T cells


- Target cell surface tumor-associated antigens (TAAs) independent of HLA
- “Public” cell surface antigens

TCR⁺ T cells

- Target intracellular TAAs dependent on HLA
- “Private” intra-cellular antigens


NK cells

- Target tumor with loss of HLA
- No “antigens”




Building on the Progress of MDACC Trials for CAR⁺ T Therapy

CD19-directed CAR⁺ T therapies utilizing Sleeping Beauty (SB) non-viral gene integration after hematopoietic stem-cell transplantation (HSCT)



Infusion of **autologous T cells** in patients with advanced non-Hodgkin lymphoma (NHL)


86% of patients (n=6) remain in complete remission (CR)



Infusion of **allogeneic T cells** in patients with advanced CD19⁺ acute lymphoblastic leukemia or NHL

58% of patients (n=11/19) remain in CR

75% of patients who received haplo-HCST (n=8) remain in CR



Portfolio of Next-generation Cell Therapies

Manage the cost of immunotherapy and targeting solid tumors

CAR⁺ T cells



- CAR designs
- Cytokines
- Off-the-shelf

TCR⁺ T cells




- Personalizing by targeting neo-antigens

NK cells



- Cytokines
- Off-the-shelf
- Bioprocessing

Engineering Off-the-Shelf CAR⁺ T-Cells




- Centralized manufacturing
- T cells can be prepared in advance of need
- T cells can be shipped to multiple points of care
- T cells can be infused on demand

Strong Collaborations to Bring Therapeutics to Market



Differentiated Platforms to Fight Cancer



Intrexon Engine



Ziopharm Implementation

- Harnessing synthetic biology to develop and implement a pipeline of therapeutics
- Update on clinical trials by year end 2015
- New trials anticipated in 2016

Harnessing the future

2015

2016+

Viral Gene Therapy

Ad-RTS-IL-12

Glioma and Breast

Expand Indications

Combinations

2015

2016+

Adoptive Cell Therapy

Hematological (ALL/NHL/CLL)

Hematological (AML/MDS)

CAR Design

CAR & Cytokine

Solid Tumors

NK cells

TCR

Off-the-shelf